McKesson Compile’s Post

Have you seen the white paper by DTA member, IDEA Pharma | From R&D to RxD, A Review of Four Promising Digital Health Solutions in Oncology: Digital Therapeutics, Remote Monitoring, Clinical Decision Support and Wellness Applications? Read the full paper: https://lnkd.in/eS2wz-gh #IDEAPharma #DTA #DigitalTherapeuticsAlliance #DigitalTherapeutics #DigitalHealth #DigitalHealthSolutions #MedTech #HealthTech

What are the critical insights from the accelerated approval for Sotorasib?   I sat down with Oncology Data Advisor and Matthew Hadfield, DO to discuss how this landmark drug development program highlights the need for study innovation to keep pace with today’s novel therapies. Clinical trials are a foundational pillar of the therapeutic lifecycle, and targeted therapies are forcing drug developers and regulatory bodies to adapt.    Drawing on first hand experiences of seeing novel drugs through the regulatory process, we discuss how developers can integrate a more robust dose exploration strategy in earlier phases. Sharing these and other essential takeaways can help advance the entire field and most importantly, improve patient outcomes.    Visit the link below to hear the full interview. https://lnkd.in/e-Gy3U5Z

At Olive Ridley Advisory (ORA), At ORA, we believe that knowledge is power. Our mission is to empower businesses with actionable insights and strategic guidance. Our expertise, combined with cutting-edge technology, allows us to address critical challenges across various domains. One of the key services in our portfolio is conference coverage, specifically focusing on pharmaceutical conferences. Here are the highlights of our comprehensive conference coverage: ● Live Snapshot within 90 Minutes: We understand the urgency of real-time information. Our team swiftly summarizes abstract presentations, distilling key insights within just 90 minutes. This ensures that your clients stay informed and engaged, even during fast-paced conferences. ● Conferences Covered: We provide coverage for notable events in the pharmaceutical industry, including: §ASCO (American Society of Clinical Oncology) §ESMO (European Society for Medical Oncology) §AACR (American Association for Cancer Research) §ASH (American Society of Hematology) §EHA (European Hematology Association) These conferences serve as critical platforms for sharing groundbreaking research, clinical advancements, and industry trends. Our goal is to keep your clients up-to-date with the latest developments, enabling informed decision-making and help to shape their strategy based on these clinical updates Feel free to explore our offerings and join us in shaping the future of Pharma and healthcare! https://lnkd.in/d3hP6BNE [email protected]

At Olive Ridley Advisory (ORA), At ORA, we believe that knowledge is power. Our mission is to empower businesses with actionable insights and strategic guidance. Our expertise, combined with cutting-edge technology, allows us to address critical challenges across various domains. One of the key services in our portfolio is conference coverage, specifically focusing on pharmaceutical conferences. Here are the highlights of our comprehensive conference coverage: ● Live Snapshot within 90 Minutes: We understand the urgency of real-time information. Our team swiftly summarizes abstract presentations, distilling key insights within just 90 minutes. This ensures that your clients stay informed and engaged, even during fast-paced conferences. ● Conferences Covered: We provide coverage for notable events in the pharmaceutical industry, including: §ASCO (American Society of Clinical Oncology) §ESMO (European Society for Medical Oncology) §AACR (American Association for Cancer Research) §ASH (American Society of Hematology) §EHA (European Hematology Association) These conferences serve as critical platforms for sharing groundbreaking research, clinical advancements, and industry trends. Our goal is to keep your clients up-to-date with the latest developments, enabling informed decision-making and help to shape their strategy based on these clinical updates Feel free to explore our offerings and join us in shaping the future of Pharma and healthcare! https://lnkd.in/d3hP6BNE [email protected]

🌟 Our team is covering ASCO 2024! This is an opportunity for us to be part of the most significant gathering of oncology professionals worldwide, ASCO 2024! We are covering several CSS and oral abstract sessions across multiple indications during the conference days. ASCO 2024 Sessions at a Glance: 📊 24 Oral Abstract Sessions: Featuring over 250 oral abstract presentations 🔬 16 Clinical Science Symposia: Including 3 special cross-cutting sessions 🆕 24 Rapid Oral Abstract Sessions 📑 Over 2,000 Poster Presentations: Including Trials in Progress To get a conference summary from our analyst, write to us or DM us: 📊 Analysis of Key Presentations: 📍 Get detailed insights from plenary and oral abstract sessions, highlighting practice-changing and clinically relevant data. 📍 Receive summaries of key findings from Clinical Science Symposia and Rapid Oral Abstract Sessions 🔬 Tracking Emerging Therapies: 📍 Track emerging therapies and innovative treatment approaches presented during the conference. 📍 Identify new market entrants and potential disruptors in the oncology landscape. ⚖️ Regulatory and Collaborative Insights: 📍 Receive updates from joint sessions with FDA, NCI, AACR, and ECO, providing crucial regulatory perspectives. 📍 Learn about collaborative strategies discussed in workshops and case-based panels. Our expertise at ASCO 2024 will empower pharmaceutical companies to stay ahead of the curve, optimize their strategies, and drive success in the oncology field #ASCO24 #ImprovingPatientOutcomes #CancercareFromComforttoCure #ConferenceCoverage #CompetitiveIntelligence #eQuantX

Reputation of Pharma companies. What are the attributes of the leading oncology companies with whom HCPs engage. And indeed - who are the leading companies? Our ‘Voice of the Customer Oncology Perceptions’ report  is now available and will provide you with insights regarding the characteristics of leading oncology companies as perceived by the HCPs with whom they engage. What they do well, and where they can do better. Talk to us about this unique report and we can show you why 7/10 leading Pharma companies use these valuable insights. We can even show you the correlation between the companies who use our reports and how they are perceived by the HCPs . They are listening to the Voice of the Customer. Darmah Market Research - Helping companies unlock the potential to deeper understanding and enhanced engagement. #PMI  

Certainly, Yvonne when companies gain deep insights of what customers value most, and adapt their strategies accordingly the impact is evident as we have seen repeatedly with our clients.

Radiopharmaceuticals are gaining significant attention as this treatment offers key benefits including precision diagnosis, non-invasive procedures, real-time monitoring, and more. These benefits are revolutionizing the way we approach diagnosis, medical treatment, and patient care. Allucent expert Vanessa Beddo, VP, Global Head of Biostatistics Consulting, spoke at the 2024 Radiopharmaceuticals Summit, where she participated in the conversation about how radiopharmaceuticals can improve patient care and treatment outcomes in clinical trials. Her insights emphasized the critical role that analysis and study design considerations can play in delivering high quality, efficient clinical trial results for a successful development program. Check out the recent podcast with Allucent experts Sugato De, MS (VP, Regulatory Strategy, Head of MedTech) and Alex MacDonald, PhD (VP, Model Informed Drug Development), where they dive into the world of #antibodydrugconjugates (ADCs) and #radionuclide conjugates (RDCs) by exploring both the tremendous growth potential and challenges posed by these targeted oncology therapies. BioPharma Dive Listen to the podcast: https://lnkd.in/g8uSZp7X #Allucent #BringNewTherapiesToLight #Radiopharmaceuticals #PrecisionMedicine

🎉 Pharma's Patent Race: 2024 Highlights In 2024, the pharmaceutical sector saw a sharp rise in patent activity, particularly in oncology, driven by demand for innovative cancer treatments and advances in precision medicine: - Novartis: Industry leader with 154 patents, showcasing robust R&D. - Roche: Filed 131 patents, including a sector-best 54 oncology-specific patents, underscoring its focus on cancer therapies. - Johnson & Johnson & Bristol Myers Squibb: Strong balance across overall and oncology patents. - Seagen & Daiichi Sankyo: Smaller players excelling in specialized oncology R&D with 30 and 22 patents respectively. 💊 These patents reflect a shift toward targeted therapies and personalized medicine, promising impacts on market dynamics and patient care. 📊 Data source: Brian K. Buntz, via Google Cloud’s BigQuery. 👉 Picture/Post Source: Maryam Daneshpour - follow her!! #pharma #biopharma #oncology #pharmaceutical

🚀 Exciting News for IBD Plexus Members! 🚀 We're thrilled to celebrate two major acquisitions that could significantly impact the future of IBD treatment: 🌟 Celsius Therapeutics has been acquired by AbbVie! Celsius developed CEL383, an anti-TREM1 antibody poised to be a first-in-class molecule in IBD, having completed its Phase 1 trial in healthy volunteers. 🌟 Morphic Therapeutics has been acquired by Eli Lilly! Morphic has three ongoing Phase 2 clinical trials for Crohn’s disease and ulcerative colitis, testing the efficacy of MORF-057, an oral α4β7 integrin inhibitor. Both companies have leveraged IBD Plexus data and biological samples to drive precision medicine strategies forward. We're excited to see the positive impact these novel medications will bring to patients. The Crohn’s & Colitis Foundation is dedicated to supporting IBD researchers in their quest to bring groundbreaking treatments to patients. Learn more about the data that IBD Plexus offers here: https://bit.ly/3wuIOMp #IBD #PrecisionMedicine #HealthcareInnovation #Crohnsdisease #ulcerativecolitis #CelsiusTherapeutics #MorphicTherapeutics #AbbVie #EliLilly #CrohnsColitisFoundation